»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
¼¼°èÀÇ DNA ½ÃÄö½Ì ½ÃÀå ±Ô¸ð´Â 2024³â 148¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È CAGR 18.6%·Î ¼ºÀåÇÒ Àü¸ÁÀ̰í, 2029³â ¸»¿¡´Â 348¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù.
¼¼°èÀÇ Â÷¼¼´ë ½ÃÄö½Ì ÀÓ»ó ÀÀ¿ë ½ÃÀå ±Ô¸ð´Â 2023³â 219¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È CAGR 19.3%·Î ¼ºÀåÇÒ Àü¸ÁÀ̰í 2028³â¿¡´Â 529¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù.
¼¼°èÀÇ RNA ½ÃÄö½Ì ½ÃÀå ±Ô¸ð´Â 2024³â 43¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È CAGR 19.1%·Î ¼ºÀåÇÒ Àü¸ÁÀ̰í, 2029³â ¸»¿¡´Â 103¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù.
DNA ¹× RNA ÇÕ¼ºÀº µ¥¿Á½Ã¸®º¸½º ÇÙ»ê(DNA)°ú ¸®º¸ÇÙ»ê(RNA)À» ÀΰøÀûÀ¸·Î »ý»êÇÕ´Ï´Ù. DNA¿Í RNA¸¦ ±¸ÃàÇÏ´Â ÇÕ¼º ±â¼úÀÇ °³¹ßÀº »ýüÇÐÀ» ÀÌÇØÇÏ°í ¿£Áö´Ï¾î¸µÇÏ´Â ´É·ÂÀ» Çâ»ó ½ÃÄ×½À´Ï´Ù. ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå, À¯ÀüÀÚ, DNA ¹× RNA ´ÜÆí°ú °°Àº ´Ù¾çÇÑ À¯ÇüÀÇ ÇÕ¼º DNA¸¦ »ç¿ëÇÒ ¼ö ÀÖÀ¸¸ç °í°´ÀÇ ¿ä±¸¿¡ ¸Â°Ô »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇÕ¼º DNA¿Í RNA´Â ½Å¾à°ú ¹é½ÅÀÇ °³¹ß, À¯Àü¼º ÁúȯÀÇ À¯ÀüÀÚ Ä¡·á, º´¿øÃ¼¿Í Áúº´À» °ËÃâÇϱâ À§ÇÑ PCR ºÐ¼® ¹× ÇÙ»ê ±â¹Ý ¼¾¼ µîÀÇ ºÐÀÚÁø´Ü ÅøÀÇ °³¹ß¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.
DNA¿Í RNAÀÇ ÇÕ¼º ±â¼úÀº ÇÕ¼º »ý¹°ÇÐ, ºÐÀÚ À¯ÀüÇÐ, »ý¹° °øÇаú °°Àº °úÇÐ ºÐ¾ß¿¡¼ ÇʼöÀûÀÌ¸ç ´Ù¾çÇÑ ¿¬±¸, Áø´Ü ¹× Ä¡·á ¿ëµµÀÇ ¸ÂÃãÇü DNA ¹× RNA ¼¿À» »ý¼ºÇÕ´Ï´Ù. À¯Àüü ¿¬±¸ÀÇ ±Þ¼ÓÇÑ È®Àå, Ä¡·á¿ë DNA ¹× RNA Àû¿ëÀÇ Áøº¸, °³ÀÎÈµÈ ÀÇ·á ¿ä±¸ Áõ°¡´Â DNA ¹× RNA ÇÕ¼º ½ÃÀåÀÇ ÇöÀúÇÑ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. CRISPR, À¯ÀüÀÚ Ä¡·á ¹× ÇÕ¼º »ý¹°ÇÐÀÇ Çõ½ÅÀº DNA ¹× RNA ÇÕ¼º¿¡ ´ëÇÑ ¼ö¿ä°¡ ±Þ»ó½ÂÇϰí ÀÖÀ½À» º¸¿©ÁÖ¸ç Ç¥Àû Ä¡·á ¹× Çõ½ÅÀûÀÎ À¯ÀüÀÚ ¿¬±¸ ¼Ö·ç¼Ç °³¹ß¿¡ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ µµ±¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.
º» Á¶»ç ¸®ºä´Â BCC Research°¡ 2024³â¿¡ ¹ßÇàÇÑ À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦, DNA ½ÃÄö½Ì, Â÷¼¼´ë ½ÃÄö½Ì, RNA ½ÃÄö½Ì RNAi ±â¼ú ¹ÙÀÌ·¯½º º¤ÅÍ¿Í Çö󽺹̵å DNA¿¡ °üÇÑ º¸°í¼ÀÇ ÇÏÀ̶óÀÌÆ®¿Í ¹ßÃ鸦 Æ÷ÇÔÇØ, °¢°¢ ½ÃÀå °³¿ä, ½ÃÀå ¿µÇâ¿äÀÎ ¹× ½ÃÀå ±âȸÀÇ ºÐ¼®, ¹ý±ÔÁ¦ ȯ°æ, ½Å±â¼ú ¹× ±â¼ú °³¹ßÀÇ µ¿Çâ, ½ÃÀå ±Ô¸ð µîÀ» Á¤¸®Çß½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå(BIO259A)
Á¶»ç ¹üÀ§
½ÃÀå Àü¸Á
½ÃÀå ¿ä¾à
À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå °³¿ä
À¯ÀüÀÚ ÆíÁý µµ±¸ÀÇ À¯Çü
¸Þ°¡´ºÅ¬·¹¾ÆÁ¦
¾Æ¿¬ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦
Àü»ç Ȱ¼ºÈÁ¦ À¯»ç ÀÌÆåÅÍ ´ºÅ¬·¹¾ÆÁ¦
CRISPR/CRISPR °ü·Ã ´Ü¹éÁú
À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦
½ÃÀå ¿ªÇÐ
½ÃÀå ÃßÁø ÀÎÀÚ
½ÃÀå °úÁ¦
À¯ÀüÀÚ ÆíÁý Ä¡·áÀÇ »õ·Î¿î ±â¼ú°ú ±âȸ
º£À̽º ÆíÁý
ÇÁ¶óÀÓ ÆíÁý
Cas-Clover¿Í Cas-FOKl
CRISPR °£¼·°ú CRISPR Ȱ¼ºÈ
RNA ÆíÁý
À¯ÀüÀÚ ÆíÁý¿¡¼ AI
À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå ºÐ¼®
°³¿ä
Casgevy
À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº°
ºÏ¹Ì
À¯·´
½ÅÈï ½ÃÀå
À¯ÀüÀÚ ÆíÁý Ä¡·á ½ÃÀåÀÇ ESG ¼º´É
À¯ÀüÀÚ ÆíÁý ±â¾÷ÀÇ ESG ½Çõ
BCC¿¡ ÀÇÇÑ ÃÑ·Ð
Á¦3Àå ¼¼°èÀÇ DNA ½ÃÄö½Ì : ¿¬±¸, ÀÀ¿ë, ÀÓ»ó ½ÃÀå(BIO045J)
Á¶»ç ¹üÀ§
½ÃÀå Àü¸Á
½ÃÀå ¿ä¾à
½ÃÀå °³¿ä
DNAÀÇ Á߿伺
À¯ÀüÀû º¯ÀÌ¿Í ºÐ¼®
NGS
TGS
¿¬±¸¿Í ÀÀ¿ë
R&D ¿ëµµ
ÀÀ¿ë ºÐ¾ß
D2C
¹ÙÀÌ¿ÀÀǾàǰ
³ó¾÷
¹ýÀÇÇÐ
¸¶ÀÌÅ©·Î¹ÙÀÌ¿È
ÇÕ¼º »ý¹°ÇÐ
½ÃÀå ¿ªÇÐ
½ÃÀå ÃßÁø ÀÎÀÚ
½ÃÀå ¾ïÁ¦ ÀÎÀÚ
½ÅÈï±â¼ú
·Õ ¸®µå ½ÃÄö½Ì ±â¼ú
SMRT ½ÃÄö½Ì
³ª³ëÆ÷¾î ½ÃÄö½Ì
°ø°£ À¯ÀüüÇÐ ¹× Àü»çüÇÐ
´ÜÀÏ ¼¼Æ÷ DNA ½ÃÄö½Ì
ÃÊÀúÅõÀÔ ½ÃÄö½Ì
CRISPR-Cas9 ¹× À¯ÀüÀÚ ÆíÁý°ú ½ÃÄö½Ì ±â¼úÀÇ ÅëÇÕ
DNA ½ÃÄö½Ì¿¡ ÀÖ¾î¼ÀÇ AI¿Í ¸Ó½Å·¯´×
½ÃÀå ºÐ¼® : ±â¼úº°
°³¿ä
NGS
TGS
»ý¾î ½ÃÄö½Ì
ÆÄÀÌ·Î ½ÃÄö½Ì
½ÃÀå ºÐ¼® : Áö¿ªº°
ºÏ¹Ì
À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
±âŸ Áö¿ª
DNA ½ÃÄö½Ì ¾÷°èÀÇ ESG ¼º´É
ȯ°æ ¼º´É
»çȸÀû ¼º´É
°Å¹ö³Í½º ¼º´É
DNA ½ÃÄö½Ì ¾÷°è¿¡¼ ESG À§Çè Æò°¡
BCC¿¡ ÀÇÇÑ ÃÑ·Ð
Á¦4Àå ¼¼°èÀÇ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀå : »õ·Î¿î ÀÓ»ó ¿ëµµ(BIO126E)
Á¶»ç ¹üÀ§
½ÃÀå Àü¸Á
½ÃÀå ¿ä¾à
½ÃÀå °³¿ä
¾×ü ¹× Á¶Á÷ »ý°Ë
ÀÓ»ó NGSÀÇ ¼ºÀå ¿äÀÎ
ÁÖ¿ä µ¿Çâ
½ÃÀå ¿ªÇÐ
½ÃÀå ÃßÁø ÀÎÀÚ
½ÃÀå ¾ïÁ¦ ÀÎÀÚ
Â÷¼¼´ë ½ÃÄö½ÌÀÇ »õ·Î¿î ±â¼ú
¿¬±¸°³¹ßÀÇ ´ëó¿Í ÇÁ·Î±×·¥
100¸¸ °³ ÀÌ»óÀÇ °Ô³ð
Ä¡·á ¹× °Ë»ç Á¢±Ù¼º(ACTT)
Æ÷°ýÀû À¯Àüü ÇÁ·ÎÆÄÀϸµ ¿¬ÇÕ(ACGP)
¾ÆÇÁ¸®Ä« º´¿øÃ¼ À¯ÀüüÇÐ ÀÌ´Ï¼ÅÆ¼ºê
Ç÷¾× ÇÁ·ÎÆÄÀϸµ ¾ÆÆ²¶ó½º
¾Ï-ID
¾Ï ¹®¼¦ ÇÁ·Î±×·¥
Áß±¹ Á¤¹Ð ÀÇÇÐ ÀÌ´Ï¼ÅÆ¼ºê
ClinGen
CTC Æ®·¦ ÄÁ¼Ò½Ã¾ö
diaRNAÁø´Ü ÇÁ·ÎÁ§Æ®
Á¶±â ¾Ï ¹ß°ß ÄÁ¼Ò½Ã¾ö
EpiFemCare
ÇÁ¶û½º À¯Àüü ÀÇÇÐ °èȹ
Friends of Cancer ¿¬±¸ ÇÁ·ÎÁ§Æ®
À¯Àüü ÀÇÇÐ ½º¿þµ§
HCA-Àå±â
Àΰ£ ¼¼Æ÷ Áöµµ
Àΰ£ ¸é¿ªÇÐ °èȹ
¸é¿ª ¸ð´ÏÅÍ ÄÁ¼Ò½Ã¾ö
¿µ»ó ¹× À¯Ã¼ÀÇ ÅëÇÕ-±â¹Ý Á¾¾ç ¸ð´ÏÅ͸µ ¾Ï Ä¡·á ÇÁ·Î±×·¥
Intervene
¾Ï Ä¡·á °³¼±À» À§ÇÑ ¾×ü »ý°Ë ¹× ¿µ»ó
¾×ü »ý°Ë ±â¹Ý ¾Ç¼º Á¾¾ç Á¶±â °ËÁø ±â¼ú ¿¬±¸ °³¹ß ÇÁ·ÎÁ§Æ®
°£¾Ï Á¶±â °ËÁø Á¾ÇÕ ¿¹¹æ ¹× °ü¸® ÇÁ·ÎÁ§Æ®
¾Æ½Ã¾Æ °³ÀÎ ¸ÂÃãÇü ÀǷḦ À§ÇÑ Æó¾Ï À¯Àüü °ËÁø »ç¾÷
¹é¸¸ º£Å×¶û ÇÁ·Î±×·¥
ÀÇ·á À¯Àüü ÀÌ´Ï¼ÅÆ¼ºê
MedSeq
½ÃÀå ºÐ¼® : Áúȯ Ä«Å×°í¸®º°
°³¿ä
½ÃÀå ºÐ¼® : Áö¿ªº°
ºÏ¹Ì
À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
Â÷¼¼´ë ½ÃÄö½Ì ¾÷°è¿¡¼ ESG ¼º´É
»ç·Ê ¿¬±¸
BCC¿¡ ÀÇÇÑ °ßÇØ
Á¦5Àå ¼¼°èÀÇ RNA ½ÃÄö½Ì ½ÃÀå : °¢Á¾ ±â¼ú(BIO147B)
Á¶»ç ¹üÀ§
½ÃÀå Àü¸Á
½ÃÀå ¿ä¾à
½ÃÀå °³¿ä
±â¼ú ¹è°æ
Àü»çüÇÐ ±â¼ú
Àü»çüÇи¦ À§ÇÑ RNA ½ÃÄö½Ì
RNA-Seq ½ÇÇè ¿öÅ©Ç÷οì
RNA ½ÃÄö½ÌÀÇ ±ÔÁ¦ »óȲ
¼ºÀå Àü·« Á¦¾È
½ÃÀå ¿ªÇÐ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
½ÃÀå ±âȸ
RNA ½ÃÄö½Ì ½ÃÀåÀÇ ½Å±â¼ú°ú ¹ßÀü
´ÜÀÏ ¼¼Æ÷ RNA ½ÃÄö½Ì
±âŸ ½ÅÈï ´ÜÀÏ ¼¼Æ÷ ±â¼ú
½ÃÀå ºÐ¼® : RNA ½ÃÄö½Ì Á¦Ç°
±â±â
µµ±¸ ¹× ½Ã¾à
¼ÒÇÁÆ®¿þ¾î ¹× ¼ºñ½º
½ÃÀå ºÐ¼® : Áö¿ªº°
°³¿ä
ºÏ¹Ì
À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
±âŸ Áö¿ª
RNA ½ÃÄö½Ì ½ÃÀå¿¡¼ÀÇ Áö¼Ó°¡´É¼º : ESG °üÁ¡
RNA ½ÃÄö½Ì ¾÷°è¿¡¼ ESG ½Çõ
ȯ°æ ¼º´É
»çȸÀû ¼º´É
°Å¹ö³Í½º ¼º´É
BCC¿¡ ÀÇÇÑ ÃÑ·Ð
Á¦6Àå ¼¼°èÀÇ RNAi ±â¼ú ½ÃÀå(BIO127C)
Á¶»ç ¹üÀ§
½ÃÀå Àü¸Á
½ÃÀå ¿ä¾à
½ÃÀå °³¿ä
RNA °£¼·ÀÇ °³¿ä
RNA °£¼· : ÀÛ¿ë ¸ÞÄ¿´ÏÁò
½ÃÀÛ ´Ü°è
ÀÌÆåÅÍ ´Ü°è
ÀúºÐÀÚ °£¼· RNA(siRNA)
¸¶ÀÌÅ©·Î RNA(miRNA)
¼ÒÇü Çì¾îÇÉ RNA(shRNA)
½ÃÀå ¿ªÇÐ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
½ÃÀå °úÁ¦
RNAi ±â¼úÀÇ »õ·Î¿î ±â¼ú°ú ±âȸ
Ä¡·áÁ¦
Áø´Ü
ºñħ½ÀÀû °Ç° ¸ð´ÏÅ͸µÀ» À§ÇÑ ¼øÈ¯ miRNA Áø´Ü
³ó¾÷
±â¼úº° ½ÃÀå
Ä¡·áÁ¦
Áø´Ü
½Ã¾à°ú µµ±¸
³ó¾÷
Áö¿ªº° ½ÃÀå
°³¿ä
ºÏ¹Ì
À¯·´
½ÅÈï ½ÃÀå
RNAi ±â¼ú ¾÷°èÀÇ Áö¼Ó°¡´É¼º : ESG °üÁ¡
ȯ°æ¿¡ÀÇ ´ëó
»çȸ °øÇå Ȱµ¿
°Å¹ö³Í½º ³ë·Â
»ç·Ê ¿¬±¸
BCC¿¡ ÀÇÇÑ ÃÑ·Ð
Á¦7Àå ¼¼°èÀÇ ¹ÙÀÌ·¯½º º¤ÅÍ ¹× Çö󽺹̵å DNA ½ÃÀå : °¢Á¾ ±â¼ú(BIO192B)
Á¶»ç ¹üÀ§
½ÃÀå Àü¸Á
½ÃÀå ¿ä¾à
½ÃÀå °³¿ä
¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á
½ÃÀå ¿ªÇÐ
½ÃÀå ÃßÁø ÀÎÀÚ
½ÃÀå °úÁ¦
»õ·Î¿î ±â¼ú°ú ±âȸ
¹ÙÀÌ·¯½º º¤ÅÍ »ý»ê¿¡¼ AI
µµ±âº» DNA
FRAGment Recycler : Çö󽺹̵å DNA ÇÕ¼ºÀÇ ½Å±â¼ú
¹ÙÀÌ·¯½º º¤ÅÍ ¹× Çö󽺹̵å DNA ±â¼ú ½ÃÀå : Á¦Ç° À¯Çüº°
¹ÙÀÌ·¯½º º¤ÅÍ ¹× Çö󽺹̵å DNA ±â¼ú ½ÃÀå : ¿ëµµº°
¹ÙÀÌ·¯½º º¤ÅÍ ¹× Çö󽺹̵å DNA ±â¼ú ½ÃÀå : Áö¿ªº°
°³¿ä
ºÏ¹Ì
À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
¶óƾ¾Æ¸Þ¸®Ä«
±âŸ Áö¿ª
¹ÙÀÌ·¯½º º¤ÅÍ ¹× Çö󽺹̵å DNA ±â¼ú ½ÃÀå¿¡¼ÀÇ Áö¼Ó°¡´É¼º : ESG °üÁ¡
ȯ°æ ¿äÀÎ
»çȸÀû ¿äÀÎ
°Å¹ö³Í½º ¿äÀÎ
´ë±â¾÷ÀÇ ESG ¼º´É
ÁÖ¿ä ±â¾÷ÀÇ ESG ¼º´É
Lonza : ESG ¼º´É
Thermo Fisher : ESG ¼º´É
ÃÑ·Ð
Á¦8Àå ºÎ·Ï
KTH
The global market for DNA sequencing is expected to grow from $14.8 billion in 2024 and is projected to reach $34.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024 to 2029.
The global market for clinical applications of next-generation sequencing is estimated to increase from $21.9 billion in 2023 to reach $52.9 billion by 2028, at a CAGR of 19.3% from 2023 through 2028.
The global market for RNA sequencing is expected to grow from $4.3 billion in 2024 and is projected to reach $10.3 billion by the end of 2029, at a CAGR of 19.1% during the forecast period of 2024 to 2029.
Research Review Scope
DNA and RNA synthesis artificially manufactures deoxyribose nucleic acid (DNA) and ribonucleic acid (RNA). Developing synthetic techniques to construct DNA and RNA has improved the ability to understand and engineer biology. Different types of synthesized DNA, such as oligonucleotides, genes, and DNA and RNA fragments, are available and can be utilized per the customer's needs. Synthetic DNA and RNA are used to develop new drugs and vaccines, gene therapies for genetic disorders, and the development of molecular diagnostic tools, including polymerase chain reaction (PCR) assays and nucleic-acid-based sensors, to detect pathogens and diseases.
DNA and RNA synthesis technology is vital in scientific fields such as synthetic biology, molecular genetics, and bioengineering, creating custom DNA and RNA sequences for various research, diagnostic, and therapeutic applications. The rapid expansion of genomics research, advancements in therapeutic DNA and RNA applications, and the growing need for personalized medicine are driving exceptional growth in the DNA & RNA synthesis market. The innovations in CRISPR, gene therapy, and synthetic biology show that the demand for DNA and RNA synthesis has risen sharply, positioning it as a pivotal tool in developing targeted treatments and innovative genetic research solutions.
Research Reviews from BCC Research provide market professionals with concise market coverage within a specific research category. This 2024 Research Review of DNA and RNA synthesis technology provides a sampling of the type of quantitative market information, analysis, and guidance that BCC Research has been developing since its inception in 1971 to help its customers make informed business decisions. This Research Review includes highlights and excerpts from the following reports published by BCC Research in 2024:
BIO259A Gene Editing Therapeutics Market
BIO045J Global DNA Sequencing: Research Applied and Clinical Markets
BIO126E Next-generation Sequencing: Emerging Clinical Applications and Global Markets
BIO147B RNA Sequencing: Technologies and Global Markets
BIO127C RNAi Technologies and Global Markets
BIO192B Viral Vector and Plasmid DNA: Technologies and Global Markets
After you survey the excerpts in this Research Review, we encourage you to follow up on these topics by checking out the full market research reports associated with each topic. BCC Research looks forward to serving your market intelligence needs in the future.
Table of Contents
Chapter 1 Foreword
Chapter 2 Gene Editing Therapeutics Market (BIO259A)
Scope of Report of Gene Editing Therapeutics
Market Outlook of Gene Editing Therapeutics
Market Summary
Market Overview of Gene Editing Therapeutics
Genome-Editing Tool Types
Meganucleases
Zinc Finger Nucleases
Transcription Activator-like Effector Nucleases
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-Associated Protein 9
Gene editing Therapeutics
Market Dynamics of Gene Editing Therapeutics
Market Driver
Market Challenges
Emerging Technologies and Opportunities of Gene Editing Therapeutics
Base Editing
Prime Editing
Cas-Clover and Cas-FOKl
CRISPR Interference and CRISPR Activation
RNA Editing
Artificial Intelligence in Genome Editing
Market Analysis of Gene Editing Therapeutics
Overview
Casgevy
Market of Gene Editing Therapeutics by Region
North America
Europe
Emerging Markets
ESG Performance in Gene Editing Therapeutics Market
ESG Practices in the Gene Editing Companies
Concluding Remarks from BCC Research
Chapter 3 Global DNA Sequencing: Research, Applied and Clinical Markets (BIO045J)
Scope of Report of DNA Sequencing: Research, Applied and Clinical Markets
Market Outlook of DNA Sequencing: Research, Applied and Clinical Markets
Market Summary of DNA Sequencing: Research, Applied and Clinical Markets
Market Overview of DNA Sequencing: Research, Applied and Clinical Markets
Importance of DNA
Genetic Variation and Analysis
NGS (Second-generation Sequencing)
TGS (Long-read Sequencing)
Research and Applied Applications
R&D Applications
Applied Applications
Direct to Consumer
Biopharma
Agriculture
Forensics
Microbiome
Synthetic Biology
Market Dynamics of DNA Sequencing: Research, Applied and Clinical Markets
Market Driver
Market Restraint
Emerging Technologies of DNA Sequencing: Research, Applied and Clinical Markets
Long-read Sequencing Technologies
SMRT Sequencing
Nanopore Sequencing
Spatial Genomics and Transcriptomics
Single-cell DNA Sequencing
Ultra-low Input Sequencing
CRISPR-Cas9 and Genome-editing Integration with Sequencing Technologies
AI and Machine Learning in DNA Sequencing
Market Breakdown of DNA Sequencing: Research, Applied and Clinical Markets by Technology
Overview
NGS
TGS
Sanger Sequencing
Pyrosequencing
Market Breakdown of DNA Sequencing: Research, Applied and Clinical Markets by Region
North America
Europe
Asia-Pacific
Rest of the World
ESG Performance in DNA Sequencing Industry
Environmental Performance
Social Performance
Governance Performance
ESG Risk Ratings in the DNA Sequencing Industry
Concluding Remarks from BCC Research
Chapter 4 Next-generation Sequencing: Emerging Clinical Applications and Global Markets (BIO126E)
Scope of Report of Next-generation Sequencing
Market Outlook of Next-generation Sequencing
Market Summary of Next-generation Sequencing
Market Overview of Next-generation Sequencing
Liquid and Tissue Biopsy
Growth Drivers of Clinical NGS
Key Trends
Market Dynamics of Next-generation Sequencing
Market Driver
Market Restraint
Emerging Technologies of Next-generation Sequencing
R&D Initiatives and Programs
1+ Million Genomes
Access to Treatment and Testing (ACTT)
Access to Comprehensive Genomic Profiling Coalition (ACGP)
Africa Pathogen Genomics Initiative
Blood Profiling Atlas
Cancer-ID
Cancer Moon Shots Program
China Precision Medicine Initiative
ClinGen
CTC Trap Consortium
diaRNAgnosis Project
Early Cancer Detection Consortium
EpiFemCare
France Genomic Medicine Plan
Friends of Cancer Research Project
Genomic Medicine Sweden
HCA-Organoid
Human Cell Atlas
Human Immunomics Initiative
Immunomonitor Consortium
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program
Intervene
Liquid Biopsies and Imaging for Improved Cancer Care
Liquid Biopsy-Based Malignant Tumor Early Screening Technology Research and Development Project
Liver Cancer Early Screening Comprehensive Prevention and Control Project
Lung Cancer Genomic Screening Project for Individualized Medicine in Asia
Million Veteran Program
Medical Genome Initiative
MedSeq
Market Breakdown of Next-generation Sequencing by Disease Category
Overview
Market Breakdown of Next-generation Sequencing by Region
North America
Europe
Asia-Pacific
ESG Performance in Next-generation Sequencing Industry
Case Study
BCC Research Viewpoint
Chapter 5 RNA Sequencing: Technologies and Global Markets (BIO147B)
Scope of Report of RNA Sequencing
Market Outlook of RNA Sequencing
Market Summary of RNA Sequencing
Market Overview of RNA Sequencing
Technology Background
Transcriptomics Technologies
RNA Sequencing for Transcriptomics
RNA-Seq Experimental Workflow
Regulatory Landscape of RNA Sequencing
Growth Strategy Recommendations
Market Dynamics of RNA Sequencing
Market Drivers
Market Restraints
Market Opportunity
Emerging Technologies and Developments of RNA Sequencing Market
Single-Cell RNA Sequencing
Other Emerging Single-Cell Technologies
Market Breakdown of RNA Sequencing by Product
Instruments
Tools and Reagents
Software and Services
Market Breakdown of RNA Sequencing by Region
Overview
North America
Europe
Asia-Pacific
Rest of the World
Sustainability in RNA Sequencing Market: ESG Perspective
ESG Practices in the RNA Sequencing Industry
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks from BCC Research
Chapter 6 RNAi Technologies and Global Markets ( BIO127C)
Scope of Report of RNAi Technologies
Market Snapshot of RNAi Technologies
Market Summary of RNAi Technologies
Market Overview of RNAi Technologies
RNA Interference Overview
RNA Interference: Mechanism of Action
Initiation Phase
Effector Phase
Small Interfering RNAs (siRNAs)
MicroRNAs (miRNAs)
Small Hairpin RNAs (shRNAs)
Market Dynamics of RNAi Technologies
Market Drivers
Market Challenges
Emerging Technologies and Opportunities of RNAi Technologies
Therapeutics
Diagnostics
Circulating miRNA Diagnostics for Non-invasive Health Monitoring
Agriculture
Market for RNAi Technology by Technology
Therapeutics
Diagnostics
Reagents and Tools
Agriculture
Market for RNAi Technology by Region
Overview
North America
Europe
Emerging Markets
Sustainability in RNAi Technology Industry: An ESG Perspective
Environmental Initiatives
Social Initiatives
Governance Initiatives
Case Study
Concluding Remarks from BCC
Chapter 7 Viral Vector and Plasmid DNA: Technologies and Global Markets (BIO192B)
Scope of Report of Viral Vector and Plasmid DNA
Market Outlook of Viral Vector and Plasmid DNA
Market Summary of Viral Vector and Plasmid DNA
Market Overview of Viral Vector and Plasmid DNA
Cell and Gene Therapy
Market Dynamics of Viral Vector and Plasmid DNA
Market Driver
Market Challenges
Emerging Technologies and Opportunities of Viral Vector and Plasmid DNA
AI in Viral Vector Production
Doggybone DNA
FRAGment Recycler: A New Technology for Plasmid DNA Synthesis
Market for Viral Vector and Plasmid DNA Technologies by Product Type
Market for Viral Vector and Plasmid DNA Technologies by Application
Market for Viral Vector and Plasmid DNA Technologies by Region
Overview
North America
Europe
Asia-Pacific
Latin America
Rest of the World
Sustainability in the Market for Viral Vector and Plasmid DNA Technologies: An ESG Perspective
Environmental Factors
Social Factors
Governance Factors
ESG Performance Among Major Companies
ESG Performance of Select Companies
Lonza: ESG Performance
Thermo Fisher: ESG Performance
Conclusion
Chapter 8 Appendix
Methodology
Analyst's Credentials